Lenovo Launches GPU Advanced Services to Help Boost AI Workload Performance by Up to 30%
30.9.2025 15:00:00 CEST | Business Wire | Press Release
With GPU demand outpacing enterprise deployment capacity, Lenovo today launched GPU Advanced Services to help customers boost workload performance by up to 30% and accelerate AI adoption.1 Enterprises can achieve these gains through optimized GPU deployment and tuning delivered by Lenovo experts, based on internal performance evaluations. For businesses, that means faster time-to-market for AI innovation and reduced infrastructure costs by avoiding underutilized GPUs.
“Enterprises are moving rapidly to operationalize AI, but many still struggle with the complexity of GPU infrastructure deployment,” said Steven Dickens, CEO and Principal Analyst of HyperFRAME Research. “Lenovo’s approach addresses this challenge by helping IT teams deploy faster, optimize performance, and scale confidently, which is exactly what the market needs as AI use cases become mainstream.”
As AI adoption surges, enterprises need scalable GPU infrastructure to support high-performance workloads. Lenovo GPU Advanced Services provide guided support to help enterprises design, deploy, and operate GPU-based systems efficiently. Taking a services-first approach, Lenovo enables enterprises to maximize existing investments and scale AI without being locked into proprietary stacks.
"With certified experts and deep platform integration, Lenovo helps enterprises deploy GPU infrastructure faster and run workloads more reliably, reducing risk and unlocking the full potential of their AI investments,” said Linda Yao, VP and General Manager, Hybrid Cloud & AI Solutions, Lenovo.
GPU Advanced Services align with validated Lenovo Hybrid AI Advantage™ solutions such as the Lenovo Hybrid AI 285 platform, enabling scalable deployment from a single node to multi-nodes with customizable AI software stack and services. Designed for high-performance workloads such as generative AI, real-time video processing, and content creation, these services address critical gaps in in-house expertise, infrastructure complexity, and performance tuning.
GPU Advanced Services: Flexible Options for Every Stage
GPU Advanced Services includes three modular options that can be purchased individually or combined, giving enterprises access to Lenovo experts at the stage that best fits their GPU adoption journey and avoiding a one-size-fits-all bundle.
- GPU Plan & Design Services– For organizations just beginning their AI journey, this service provides workload assessment, solution sizing, technology selection, and architecture planning to establish the right foundation.
- GPU Implementation Services – For teams ready to deploy, Lenovo experts deliver architecture documentation, stack configuration, deployment guidance, and knowledge transfer so systems are set up correctly and efficiently.
- GPU Managed Services – For enterprises running production AI, this service delivers ongoing optimization, updates, and recovery support, including patching and compliance, across hybrid and on-premises GPU environments.
Enterprises can accelerate their AI journey with Lenovo AI Fast Start, rapidly identifying and validating use cases before scaling confidently into production with GPU Advanced Services.
Proven Impact in Key Industries
Lenovo GPU Advanced Services ease the load on IT teams by streamlining deployment and creating a faster, lower-risk path from pilot to production. The services are designed to address challenges common across industries where AI is transforming operations:
- Healthcare – AI-assisted diagnostics with real-time insights help improve the speed and accuracy of patient care.
- Automotive – Managed services can help optimize edge AI models that power autonomous and connected vehicle systems.
- Media and Entertainment – GPU tuning can enhance real-time rendering and content production workflows, enabling creators to deliver richer experiences more efficiently.
- Cirrascale Cloud Services – Cut GPU deployment time by more than 40% with Lenovo expertise, accelerating AI innovation across customer environments.
A Proven Track Record in High-Performance GPU Solutions
Lenovo GPU Advanced Services offer flexible engagement backed by proven expertise in optimizing GPU infrastructure for performance and scalability. Built on Lenovo ThinkSystem and High-Performance Compute platforms, these services sit on top of GPU-rich Lenovo systems, ensuring customers maximize their hardware investments without being locked into a single platform.
Lenovo also brings unmatched leadership in advanced computing, ranked the #1 supercomputer provider for seven consecutive years2, #1 in x86 server reliability, and among the top in security.3 This trusted foundation ensures enterprises can scale AI infrastructure with confidence.
Discover how Lenovo GPU Advanced Services can help enterprises simplify management and scale AI with confidence at: http://lenovo.com/us/en/Solutions/Hybrid_Cloud_Services/GPU_Advanced_Services.
About Lenovo
Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
[1] Based on Lenovo internal performance evaluations of optimized GPU deployment and tuning.
[2] Supercomputing leadership — Lenovo remains the world’s #1 supercomputer provider by number of systems on the June 2025 TOP500 list. See TOP500 list statistics and vendor share; Lenovo also reiterated #1 status at ISC 2025.
[3] x86 server reliability & security — Independent ITIC studies report Lenovo ThinkSystem x86 servers with the best uptime for 11 straight years (latest report referenced February 2025) and among the most secure platforms in ITIC’s 2025 server security survey. See LenovoPress ITIC summary and coverage of the 2025 ITIC security survey; additional 2024 survey recap also confirms leadership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930144708/en/
Contacts
Zeno Group for Lenovo: lenovossg@zenogroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom